Redeye: Herantis Pharma - Soon again a (stronger) clinical company
Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– an engineered derivative of its previous lead drug CDNF that allows for non-invasive administration. We slightly raise our base case to SEK 24 per share (22) and expect Herantis to take the important step back into the clinic now in H1 2023.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.